Transcriptomic change of ARDI1A mutant bladder cancer cell line treated with CPI-0209 or induced ARID1A expression
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 24 samples: 24 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersCancer research · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE176358_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA735952 and SRA study SRP323193. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 24 sample titles: 24 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM5363151 1_EV_DMSO_A
- GSM5363152 2_EV_DMSO_B
- GSM5363153 3_EV_DMSO_C
- GSM5363154 4_EV_DX_DMSO_A
- GSM5363155 5_EV_DX_DMSO_B
- GSM5363156 6_EV_DX_DMSO_C
- GSM5363157 7_EV_0209_A
- GSM5363158 8_EV_0209_B
- GSM5363159 9_EV_0209_C
- GSM5363160 10_EV_DX_0209_A
- GSM5363161 11_EV_DX_0209_B
- GSM5363162 12_EV_DX_0209_C
- GSM5363163 13_A1A_DMSO_A
- GSM5363164 14_A1A_DMSO_B
- GSM5363165 15_A1A_DMSO_C
- GSM5363166 16_A1A_DX_DMSO_A
- GSM5363167 17_A1A_DX_DMSO_B
- GSM5363168 18_A1A_DX_DMSO_C
- GSM5363169 19_A1A_0209_A
- GSM5363170 20_A1A_0209_B
- GSM5363171 21_A1A_0209_C
- GSM5363172 22_A1A_DX_0209_A
- GSM5363173 23_A1A_DX_0209_B
- GSM5363174 24_A1A_DX_0209_C
- GSE176477 Epigenomic change of ARDI1A mutant bladder cancer cell line treated with CPI-0209 or induced ARID1A expression 48 samples shares cpi-0209, ardi1a, arid1a, bladder, treated, induced, change, mutant
- GSE176493 Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma 252 samples shares cpi-0209, arid1a, mutant
- GSE214886 Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer 12 samples shares bladder, induced
- GSE273798 Expansion of peripheral T cell clonotypes predict response in patients with small cell neuroendocrine bladder and prostate cancers treated with chemo-immunotherapy in a phase I clinical trial [bulkRNA-Seq] 10 samples shares bladder, treated
- GSE193754 Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2 - untreated 6 samples shares bladder, treated
- GSE176490 Study of CPI-0209 in patients with advanced tumors. 106 samples shares cpi-0209
- GSE230036 ARID1A Mutations Promote Immune Evasion of Follicular Lymphoma Through Reduced FAS-Mediated Apoptosis by Hindering RUNX3-ETS1 Cooperativity. 30 samples shares arid1a
- GSE254867 Deciphering the novel regulatory mechanisms and biological implications of ARID1A C-terminal missense mutations in cancer [RNA-seq] 27 samples shares arid1a
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.